Jasuja Ravi, Pencina Karol M, Lawney Brian, Stephens-Shields Alisa J, Ellenberg Susan S, Snyder Peter J, Bhasin Shalender
Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Andrology. 2025 Mar;13(3):439-446. doi: 10.1111/andr.13707. Epub 2024 Aug 2.
Testosterone, estradiol, and dihydrotestosterone share common ligand binding sites on sex hormone binding globulin and albumin. It is unknown whether and how changes in testosterone, dihydrotestosterone, and estradiol concentrations during testosterone replacement therapy affect free testosterone fraction.
To determine the effect of changes in testosterone, dihydrotestosterone, and estradiol concentrations on free testosterone fraction during testosterone replacement therapy of men with hypogonadism.
Using data from the Testosterone Trials, we assessed the association of changes in total testosterone, estradiol, and dihydrotestosterone concentrations over 12 months of testosterone replacement therapy with changes in free testosterone fraction, measured using equilibrium dialysis. We used random forests to evaluate the associations of predicted mean changes in free testosterone fraction with changes in circulating concentrations of each hormone at low, mean, or high change in the other two hormones.
Testosterone replacement therapy not only increased total testosterone, dihydrotestosterone, estradiol, and free testosterone concentrations, but also the percent free testosterone, even though sex hormone binding globulin levels did not change. The predicted changes in free testosterone fraction during testosterone replacement therapy exhibited a non-linear relationship with changes in each of total testosterone, dihydrotestosterone, and estradiol concentrations. Greater increases in testosterone, dihydrotestosterone, and estradiol levels during testosterone replacement therapy were each associated with higher model-predicted percent free testosterone. Substantially smaller changes in molar concentrations of estradiol and dihydrotestosterone had a greater effect on percent free testosterone than those in testosterone.
During testosterone replacement therapy of men with hypogonadism, changes in testosterone, dihydrotestosterone, and estradiol concentrations each altered percent free testosterone non-linearly. Small changes in estradiol concentrations exerted much larger effect on the free testosterone fraction than testosterone and dihydrotestosterone, suggesting complex interactions of the three hormones with the binding proteins. Assessment of changes in free testosterone during testosterone replacement therapy should include consideration of changes in all three hormones.
睾酮、雌二醇和双氢睾酮在性激素结合球蛋白和白蛋白上具有共同的配体结合位点。目前尚不清楚睾酮替代治疗期间睾酮、双氢睾酮和雌二醇浓度的变化是否以及如何影响游离睾酮分数。
确定睾酮替代治疗性腺功能减退男性期间,睾酮、双氢睾酮和雌二醇浓度变化对游离睾酮分数的影响。
利用睾酮试验的数据,我们评估了睾酮替代治疗12个月期间总睾酮、雌二醇和双氢睾酮浓度的变化与使用平衡透析法测量的游离睾酮分数变化之间的关联。我们使用随机森林来评估在其他两种激素低、平均或高变化时,游离睾酮分数预测平均变化与每种激素循环浓度变化之间的关联。
睾酮替代治疗不仅增加了总睾酮、双氢睾酮、雌二醇和游离睾酮浓度,还增加了游离睾酮百分比,尽管性激素结合球蛋白水平没有变化。睾酮替代治疗期间游离睾酮分数的预测变化与总睾酮、双氢睾酮和雌二醇浓度的变化均呈现非线性关系。睾酮替代治疗期间睾酮、双氢睾酮和雌二醇水平的更大升高均与模型预测的更高游离睾酮百分比相关。雌二醇和双氢睾酮摩尔浓度的大幅较小变化对游离睾酮百分比的影响大于睾酮。
在性腺功能减退男性的睾酮替代治疗期间,睾酮、双氢睾酮和雌二醇浓度的变化均非线性地改变了游离睾酮百分比。雌二醇浓度的微小变化对游离睾酮分数的影响远大于睾酮和双氢睾酮,这表明这三种激素与结合蛋白之间存在复杂的相互作用。评估睾酮替代治疗期间游离睾酮的变化应考虑所有三种激素的变化情况。